Summary of Study ST001467

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000999. The data can be accessed directly via it's Project DOI: 10.21228/M8K10H This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001467
Study TitleMetabolites changes related to glucose-mediated energy production in chemotheraphy-induced cachexia
Study SummaryTargeted metabolomics platforms included amino acids and metabolites related to glucose-mediated energy production. The targeted metabolome changed with chemotheraphy-induced cachexia, and the changes were reversed with potential treatment of the cachexia. .rdb files were included as raw data files where detailed information regarding MRM transitions and internal standards can be found. Several amino acids (Gly, Pro, Gln, Taurine) were analyzed after dilution because their peak intensities were too high. Thus their analysis was performed separately from other amino acids, and their rdb files were saved in separate rdb files.
Institute
Asan Medical Center; University of Ulsan
Last NameYoo
First NameHyun Ju
Address88, Olympic-ro, 43-gil, Songpa-gu, Seoul 05505, South Korea
Emailyoohyunju@amc.seoul.kr
Phone82-02-3010-4029
Submit Date2020-08-18
Raw Data AvailableYes
Analysis Type DetailLC-MS
Release Date2020-09-21
Release Version1
Hyun Ju Yoo Hyun Ju Yoo
https://dx.doi.org/10.21228/M8K10H
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Collection:

Collection ID:CO001536
Collection Summary:Mice were randomized into five groups (n = 10 each): untreated, non-tumor-bearing mice (NTB group); untreated, tumor-bearing mice (TB group); tumor-bearing mice receiving 5-FU (5-FU group); tumor-bearing mice receiving 5-FU and 100-mg/kg BST204 (BST204100 group); and tumor-bearing mice receiving 5-FU and 200-mg/kg BST204 (BST204200 group). CT26 murine colon carcinoma cells (1 × 106) (Korean Cell Line Bank, Seoul, Korea) resuspended in 100 μL of phosphate-buffered saline were subcutaneously implanted in the right flank of 8-week-old BALB/c mice (Orient Bio, Seongnam, Korea). When tumor volumes reached 100–200 mm3 (approximately 10 days after tumor cell injection), day 0 was assigned and drug administration started for 5-FU and BST204 groups. BST204 (batch number 31037/H1) was obtained from Green Cross Wellbeing (Seongnam, South Korea), and 5-FU was purchased from Sigma-Aldrich (St. Louis, MO, USA). 5-FU (50 mg/kg) was injected intraperitoneally in 3-day cycles (1st cycle: days 0–2; 2nd cycle: days 6–8), in doses that did not exceed the clinically acceptable. BST204 (100 or 200 mg/kg) was orally administered in 5-day cycles (1st cycle: days 0–4; 2nd cycle: days 6–10). The BST204 doses were determined according to its effects on chemotherapy-related fatigue and toxicity. The endpoint of our study was determined according to IACUC guidelines, which recommend euthanasia with a maximum tumor volume of 1,500 mm3 and a BW loss of 20%. Therefore, our study period was limited to day 11. At this point, the change in tumor volumes was up to 810%, and significant cachexia was observed.
Sample Type:Blood (plasma)
Collection Location:muscle
Storage Conditions:-20℃
  logo